HENDERSON, NV / ACCESSWIRE / February 28, 2019 / Cannabis and CBD stocks have had a strong 2019. Below are several companies in the sector making news that you should research.
One that we found with an interesting technology that has yet to find much market awareness is THC Therapeutics, Inc. (THCT) has developed a soon to be patented, laboratory proven sanitizing Cannabis dryer, called the dHydronator® which can reduce moisture content of Cannabis to 10% in only 10-14 hours. The dHydronator® is dual function & also destroys harmful surface contaminants & pathogens.
Today we are highlighting: THC Therapeutics, Inc. (THCT), Scotts Miracle-Gro Company (SMG), HEXO Corp. (NYSE American: HEXO), CannTrust Holdings, Inc. (CTST), Cronos Group, Inc. (NASDAQ:CRON), and Aurora Cannabis, Inc. (ACB).
THC Therapeutics, Inc. (THCT) (Market Cap: $78.285M, Share Price: $5.50) has developed a sanitizing herb dryer, The dHydronator®, their laboratory-proven product is specifically designed for drying and sanitizing freshly harvested Cannabis and herbs. THCT’s product has been tested by two independent laboratories, testing covered over 6 strains and 9 independent tests to confirm the findings. The US patent office recently has accepted ALL 20 claims for The dHydronator®, which is HUGE. Start your research today on THCT & their Intellectual property.
Scotts Miracle-Gro Company (SMG) (Market Cap: $4.559B, Share Price: $82.36), the world’s largest marketer of branded consumer lawn and garden products, announced it will present at Raymond James & Associates’ 40th Annual Institutional Investors Conference on Monday, March 4, 2019 in Orlando, Florida. Chief Financial Officer, Randy Coleman, will discuss current business strategies.
HEXO Corp. (HEXO) (Market Cap: $1.158B, Share Price: $5.62) announced earlier this month that it has entered into a syndicated credit facility with Canadian Imperial Bank of Commerce as Sole Bookrunner, Co-Lead Arranger and Administrative Agent and Bank of Montreal as Co-Lead Arranger and Syndication Agent. Under the terms of the credit facility, the Lenders will provide HEXO up to C$65 million of secured debt financing at a rate of interest that is expected to average in the mid-to-high 5% per annum range over its three-year term.
CannTrust Holdings, Inc. (CTST) (Market Cap: $972.654M, Share Price: $9.26), a Canada-based cannabis producer, has just added itself to the list of Canadian producers to list on the NYSE. Further legitimizing an industry that was taboo only a few years ago.
Cronos Group, Inc. (CRON) (Market Cap: $3.232B, Share Price: $21.33) announced in early December that it had entered into a subscription agreement with Altria Group, Inc., one of the leading tobacco brands in the world, pursuant to which Altria agreed to make an approximately C$2.4 billion equity investment in Cronos Group on a private placement basis in exchange for common shares in the capital of the Company.
Aurora Cannabis, Inc. (ACB) (Market Cap: $7.428B, Share Price: $7.54) reported that it had agreed to acquire a majority stake in Portuguese company Gaia Pharma Ltd. at an undisclosed sum. The Company is planning to establish a medical cannabis production facility as well as for other related products as the company expands its reach to Europe.
This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to a three-month term consulting agreement with THCT dated 2/14/18. The agreement calls for 50,000 restricted shares of THCT per month. All payments were made directly by THC Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. THCT was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.